Home › Hemophilia › Washington
Hemophilia clinical trials in Washington
8 studies for Hemophilia are looking for participants at sites in Washington.
Cities in Washington
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- Washington Center for Bleeding Disorders- Site Number : 8400008, Seattle
RecruitingPhase 4
Ages 12 and older · All sexes · Updated Nov 9, 2026 · NCT06941870A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Washington Center for Bleeding Disorders, Seattle
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 3, 2026 · NCT07416604A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
- Washington Ctr Bleed Disorder, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07830732Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Washington Institute for Coagulation d/b/a WACBD, Seattle
RecruitingPhase 3
Ages 1 to 74 · Men · Updated Oct 26, 2026 · NCT05145127Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Washington Institute for Coagulation, Seattle
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 7, 2026 · NCT05568719ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Washington Center for Bleeding Disorders, Seattle
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT04398628Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
- Washington Center for Bleeding Disorders, Seattle
RecruitingPhase 1
Ages 0 to 90 · All sexes · Updated Apr 3, 2026 · NCT05500807Hemophilia A Research Program
- University of Washington, Seattle
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Feb 17, 2026 · NCT07414511From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.